CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax fo...
Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, N...
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, New Jersey, USA )
10 Jun 2021
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than l...
Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )
13 Apr 2021
Real-world evidence of the use of carfilzomib among multiple myeloma patients ac...
Prof Evangelos Terpos - University of Athens, Athens, Greece
Real-world evidence of the use of carfilzomib among multiple myeloma patients across 10 European countries and Israel ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
Real-world evidence of the use of carfilzomib to refractory to lenalidomide pati...
Prof Evangelos Terpos - University of Athens, Athens, Greece
Real-world evidence of the use of carfilzomib to refractory to lenalidomide patients ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
Real world management of multiple myeloma patients
Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina
Real world management of multiple myeloma patients ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )
8 Dec 2020
Updates in geriatric medical oncology from SIOG meeting
Dr Enrique Soto - Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zu...
Updates in geriatric medical oncology from SIOG meeting ( Dr Enrique Soto - Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico )
28 Oct 2020
Management of infection risk to myeloma patients during the COVID pandemic
Prof Heinz Ludwig - Wilhelminenspital, Center for Oncology and Hematology, Vienn...
Management of infection risk to myeloma patients during the COVID pandemic ( Prof Heinz Ludwig - Wilhelminenspital, Center for Oncology and Hematology, Vienna, Austria )
1 Oct 2020
Lenalidomide combination for multiple myeloma
Prof Xavier Leleu - Hôpital La Mileterie CHU, Poitiers, France
Lenalidomide combination for multiple myeloma ( Prof Xavier Leleu - Hôpital La Mileterie CHU, Poitiers, France )
1 Oct 2020
Mass spectrometry for the detection of minimal residual disease (MRD) in myeloma
Dr Noemí Puig - Hospital Universitario de Salamanca, Salamanca, Spain
Mass spectrometry for the detection of minimal residual disease (MRD) in myeloma ( Dr Noemí Puig - Hospital Universitario de Salamanca, Salamanca, Spain )
25 Sep 2020
Latest updates to the ESMO bone health guidelines
Prof Robert Coleman - University of Sheffield, Sheffield, UK
Latest updates to the ESMO bone health guidelines ( Prof Robert Coleman - University of Sheffield, Sheffield, UK )
22 Sep 2020
Exploring TKIs in metastatic sarcomas: Results of REGOBONE osteosarcoma cohort
Professor Jean-Yves Blay and Professor Florence Duffaud
Exploring TKIs in metastatic sarcomas: Results of REGOBONE osteosarcoma cohort ( Professor Jean-Yves Blay and Professor Florence Duffaud )
14 Nov 2019
D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk ...
Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands
D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA ( Prof Pieter Sonneveld -  Erasmus MC Cancer Institute, Rotterdam, Netherlands )
25 Sep 2019